Search
imiglucerase (Cerezyme)
Tradename: Cerezyme.
Indications:
- long-term replacement therapy for patients with type-1 Gaucher's disease Preganacy category: C, safe during pregnancy [2]
Dosage:
1) 2.5 units/kg 3 times/week up to 60 units/kg weekly to once every 4 weeks
2) 60 units/kg administered every 2 weeks is the most common dose
3) dilute total dose to volume of 100-200 mL with normal saline
4) administer over 1-2 hours at rate =< 1 unit/kg/minute
Powder for injection: (lyophilized) 200 units/vial
Pharmacokinetics:
- poor distribution to bones, lung, brain [2]
Adverse effects:
- not common (1-10%)
- hypotension, headache, dizziness, rash, pruritus, nausea, abdominal discomfort, decreased urinary frequency
Mechanism of action:
- glucocerebrosidase replacement therapy
Related
Gaucher's disease type 1 (juvenile)
Specific
Imiglucerase Parenteral
General
miscellaneous pharmacologic agent
recombinant protein; chimer
References
- Kaiser Permanente Northern California Regional Drug
Formulary, 1998
- Zimmerman, Ari